ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · IEX Real-Time Price · USD
7.00
-0.66 (-8.56%)
May 20, 2024, 3:45 PM EDT - Market open
ImmunityBio Employees
ImmunityBio had 628 employees on December 31, 2023. The number of employees decreased by 97 or -13.38% compared to the previous year.
Employees
628
Change (1Y)
-97
Growth (1Y)
-13.38%
Revenue / Employee
$481
Profits / Employee
-$956,946
Market Cap
4.84B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 628 | -97 | -13.38% |
Dec 31, 2022 | 725 | 138 | 23.51% |
Dec 31, 2021 | 587 | 416 | 243.27% |
Dec 31, 2020 | 171 | 23 | 15.54% |
Dec 31, 2019 | 148 | -13 | -8.07% |
Dec 31, 2018 | 161 | 22 | 15.83% |
Dec 31, 2017 | 139 | 57 | 69.51% |
Dec 31, 2016 | 82 | 51 | 164.52% |
Dec 31, 2015 | 31 | 16 | 106.67% |
Dec 31, 2014 | 15 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Bausch + Lomb | 13,300 |
Organon & Co. | 10,000 |
Option Care Health | 7,802 |
Doximity | 977 |
Ionis Pharmaceuticals | 927 |
Glaukos | 907 |
Lantheus Holdings | 834 |
IBRX News
- 3 days ago - Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast - Business Wire
- 13 days ago - ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® - Business Wire
- 17 days ago - ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types - Business Wire
- 20 days ago - ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association - Business Wire
- 21 days ago - What's going on with the ImmunityBio (IBRX) stock price? - Invezz
- 25 days ago - ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer - Business Wire
- 27 days ago - Here's why ImmunityBio (IBRX) stock price surged and what next - Invezz
- 27 days ago - ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Business Wire